355 related articles for article (PubMed ID: 34111562)
21. tGS ganglioside induces peculiar morphological features in grafted dopaminergic cells and promotes motor recovery in rats with unilateral lesions in the nigrostriatal dopamine pathway.
Nishino H; Hashitani T; Isobe Y; Furuyama F; Sato H; Kumazaki M; Horikomi K; Awaya A
Brain Res; 1990 Nov; 534(1-2):73-82. PubMed ID: 1981486
[TBL] [Abstract][Full Text] [Related]
22. GM1 ganglioside stimulates the regeneration of dopaminergic neurons in the central nervous system.
Toffano G; Savoini G; Moroni F; Lombardi G; Calza L; Agnati LF
Brain Res; 1983 Feb; 261(1):163-6. PubMed ID: 6132660
[No Abstract] [Full Text] [Related]
23. Nicotine-Mediated Recruitment of GABAergic Neurons to a Dopaminergic Phenotype Attenuates Motor Deficits in an Alpha-Synuclein Parkinson's Model.
Lai JI; Porcu A; Romoli B; Keisler M; Manfredsson FP; Powell SB; Dulcis D
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835612
[TBL] [Abstract][Full Text] [Related]
24. GDNF signaling implemented by GM1 ganglioside; failure in Parkinson's disease and GM1-deficient murine model.
Hadaczek P; Wu G; Sharma N; Ciesielska A; Bankiewicz K; Davidow AL; Lu ZH; Forsayeth J; Ledeen RW
Exp Neurol; 2015 Jan; 263():177-89. PubMed ID: 25448159
[TBL] [Abstract][Full Text] [Related]
25. GM1 ganglioside treatment partially reverses the nigrostriatal dopamine defect in the weaver mutant mouse.
Schneider JS; Smith MG; DiStefano L; Berrian J
Brain Res; 1994 Feb; 636(2):353-6. PubMed ID: 7912161
[TBL] [Abstract][Full Text] [Related]
26. Authentically phosphorylated α-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease.
Sato H; Arawaka S; Hara S; Fukushima S; Koga K; Koyama S; Kato T
J Neurosci; 2011 Nov; 31(46):16884-94. PubMed ID: 22090514
[TBL] [Abstract][Full Text] [Related]
27. The relationship between depletion of brain GM1 ganglioside and Parkinson's disease.
Sonnino S
FEBS Open Bio; 2023 Sep; 13(9):1548-1557. PubMed ID: 36638010
[TBL] [Abstract][Full Text] [Related]
28. Decrease in
Han S; Seo MH; Lim S; Yeo S
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884422
[TBL] [Abstract][Full Text] [Related]
29. The proSAAS Chaperone Provides Neuroprotection and Attenuates Transsynaptic α-Synuclein Spread in Rodent Models of Parkinson's Disease.
Lindberg I; Shu Z; Lam H; Helwig M; Yucer N; Laperle A; Svendsen CN; Di Monte DA; Maidment NT
J Parkinsons Dis; 2022; 12(5):1463-1478. PubMed ID: 35527562
[TBL] [Abstract][Full Text] [Related]
30. Effect of GM1 ganglioside treatment on the recovery of dopaminergic nigro-striatal neurons after different types of lesion.
Toffano G; Agnati LF; Fuxe K; Aldinio C; Consolazione A; Valenti G; Savoini G
Acta Physiol Scand; 1984 Nov; 122(3):313-21. PubMed ID: 6151339
[TBL] [Abstract][Full Text] [Related]
31. Low-Dose Aspirin Upregulates Tyrosine Hydroxylase and Increases Dopamine Production in Dopaminergic Neurons: Implications for Parkinson's Disease.
Rangasamy SB; Dasarathi S; Pahan P; Jana M; Pahan K
J Neuroimmune Pharmacol; 2019 Jun; 14(2):173-187. PubMed ID: 30187283
[TBL] [Abstract][Full Text] [Related]
32. Decreased tyrosine hydroxylase content in the dopaminergic neurons of MPTP-intoxicated monkeys: effect of levodopa and GM1 ganglioside therapy.
Kastner A; Herrero MT; Hirsch EC; Guillen J; Luquin MR; Javoy-Agid F; Obeso JA; Agid Y
Ann Neurol; 1994 Aug; 36(2):206-14. PubMed ID: 7914399
[TBL] [Abstract][Full Text] [Related]
33. Altered ion channel formation by the Parkinson's-disease-linked E46K mutant of alpha-synuclein is corrected by GM3 but not by GM1 gangliosides.
Di Pasquale E; Fantini J; Chahinian H; Maresca M; Taïeb N; Yahi N
J Mol Biol; 2010 Mar; 397(1):202-18. PubMed ID: 20114052
[TBL] [Abstract][Full Text] [Related]
34. GM1 ganglioside-induced recovery of nigrostriatal dopaminergic neurons after MPTP: an immunohistochemical study.
Hadjiconstantinou M; Mariani AP; Neff NH
Brain Res; 1989 Apr; 484(1-2):297-303. PubMed ID: 2565752
[TBL] [Abstract][Full Text] [Related]
35. Downregulation of tyrosine hydroxylase phenotype after AAV injection above substantia nigra: Caution in experimental models of Parkinson's disease.
Albert K; Voutilainen MH; Domanskyi A; Piepponen TP; Ahola S; Tuominen RK; Richie C; Harvey BK; Airavaara M
J Neurosci Res; 2019 Mar; 97(3):346-361. PubMed ID: 30548446
[TBL] [Abstract][Full Text] [Related]
36. DOPAnization of tyrosine in α-synuclein by tyrosine hydroxylase leads to the formation of oligomers.
Jin M; Matsumoto S; Ayaki T; Yamakado H; Taguchi T; Togawa N; Konno A; Hirai H; Nakajima H; Komai S; Ishida R; Chiba S; Takahashi R; Takao T; Hirotsune S
Nat Commun; 2022 Nov; 13(1):6880. PubMed ID: 36371400
[TBL] [Abstract][Full Text] [Related]
37. GM1 ganglioside rescues substantia nigra pars compacta neurons and increases dopamine synthesis in residual nigrostriatal dopaminergic neurons in MPTP-treated mice.
Schneider JS; Kean A; DiStefano L
J Neurosci Res; 1995 Sep; 42(1):117-23. PubMed ID: 8531220
[TBL] [Abstract][Full Text] [Related]
38. Brain infusion of α-synuclein oligomers induces motor and non-motor Parkinson's disease-like symptoms in mice.
Fortuna JTS; Gralle M; Beckman D; Neves FS; Diniz LP; Frost PS; Barros-Aragão F; Santos LE; Gonçalves RA; Romão L; Zamberlan DC; Soares FAA; Braga C; Foguel D; Gomes FCA; De Felice FG; Ferreira ST; Clarke JR; Figueiredo CP
Behav Brain Res; 2017 Aug; 333():150-160. PubMed ID: 28668282
[TBL] [Abstract][Full Text] [Related]
39. Mice deficient in GM1 manifest both motor and non-motor symptoms of Parkinson's disease; successful treatment with synthetic GM1 ganglioside.
Wu G; Lu ZH; Seo JH; Alselehdar SK; DeFrees S; Ledeen RW
Exp Neurol; 2020 Jul; 329():113284. PubMed ID: 32165255
[TBL] [Abstract][Full Text] [Related]
40. Intranasal administration of α-synuclein preformed fibrils triggers microglial iron deposition in the substantia nigra of Macaca fascicularis.
Guo JJ; Yue F; Song DY; Bousset L; Liang X; Tang J; Yuan L; Li W; Melki R; Tang Y; Chan P; Guo C; Li JY
Cell Death Dis; 2021 Jan; 12(1):81. PubMed ID: 33441545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
